A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants (NCT03451851)

🧪 Interventions in This Study

• Guselkumab (DRUG)
• Placebo for guselkumab (DRUG)
• Etanercept (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (39 Sites)

Showing the first 25 of 39 sites.

• Stanford University — Palo Alto, California
• University of California, San Diego — San Diego, California
• Dermatologic Surgery Specialists — Macon, Georgia
• Northwestern University Feinberg School of Medicine Ann & Robert H Lurie Children's Hospital — Chicago, Illinois
• Arlington Dermatology — Rolling Meadows, Illinois
• Windsor Dermatology — East Windsor, New Jersey
• Mt. Sinai School of Medicine — New York, New York
• Wright State Physicians Health Center — Dayton, Ohio
• Arlington Center for Dermatology — Arlington, Texas
• Dell Children's Medical Center of Central Texas — Austin, Texas
• Eastern Health Research — Box Hill,
• Royal North Shore Hospital — St Leonards,
• Veracity Clinical Research — Woolloongabba,
• Cliniques Universitaires Saint Luc — Brussels,
• Universitair Ziekenhuis Gent — Ghent,
• Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman — Liège,
• Kirk Barber Reseach Inc. — Calgary, Alberta
• Dermatology Research Institute Inc — Calgary, Alberta
• Skin Care Centre — Vancouver, British Columbia
• Universitatsklinikum Bonn — Bonn,
• Universitatsklinikum Carl Gustav Carcus Dresden — Dresden,
• Universitatsklinikum Frankfurt — Frankfurt,
• Universitatsklinikum Schleswig Holstein Kiel — Kiel,
• Praxis Dr. med. Beate Schwarz - Germany — Langenau,
• Company for Medical Study & Service Selters — Selters,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Psoriasis

• Deucravacitinib Adherence Study — Winston-Salem, North Carolina
• An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects — San Diego, California
• Psoriasis Longitudinal Assessment and Registry — Birmingham, Alabama
• Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 — Birmingham, Alabama
• Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis — Birmingham, Alabama
• Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis — Scottsdale, Arizona

Explore by condition: All Psoriasis clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.